Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 London's disastrous drug trial has serious side effects for research.

× No keyword cloud information.

12 in total

1. Payment for living organ donation should be legalised.

Authors: Amy L Friedman
Journal: BMJ Date: 2006-10-07

2. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors: Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal: J Immunol Date: 2007-04-01 Impact factor: 5.422

Review 3. A pharmacologic perspective on newly emerging T-cell manipulation technologies.

Authors: Dominic Smethurst
Journal: Br J Clin Pharmacol Date: 2013-08 Impact factor: 4.335

4. Loss of Siglec expression on T lymphocytes during human evolution.

Authors: Dzung H Nguyen; Nancy Hurtado-Ziola; Pascal Gagneux; Ajit Varki
Journal: Proc Natl Acad Sci U S A Date: 2006-05-08 Impact factor: 11.205

5. Transient regulatory T-cells: a state attained by all activated human T-cells.

Authors: Vinodh Pillai; Sterling B Ortega; C K Wang; Nitin J Karandikar
Journal: Clin Immunol Date: 2006-12-19 Impact factor: 3.969

Review 6. [Drug trials in humans. Risks in the light of the London catastrophe].

Authors: A Otte
Journal: Internist (Berl) Date: 2007-06 Impact factor: 0.743

7. Specific VEGF sequestering and release using peptide-functionalized hydrogel microspheres.

Authors: Nicholas A Impellitteri; Michael W Toepke; Sheeny K Lan Levengood; William L Murphy
Journal: Biomaterials Date: 2012-02-07 Impact factor: 12.479

8. Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.

Authors: Charles Ferte; Jean-Charles Soria; Nicolas Penel
Journal: PLoS One Date: 2011-03-02 Impact factor: 3.240

9. Model-Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab.

Authors: Bing Wang; Chi-Yuan Wu; Denise Jin; Paolo Vicini; Lorin Roskos
Journal: CPT Pharmacometrics Syst Pharmacol Date: 2017-11-23

10. Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein.

Authors: Afsaneh Sadremomtaz; Zayana M Al-Dahmani; Angel J Ruiz-Moreno; Alessandra Monti; Chao Wang; Taha Azad; John C Bell; Nunzianna Doti; Marco A Velasco-Velázquez; Debora de Jong; Jørgen de Jonge; Jolanda Smit; Alexander Dömling; Harry van Goor; Matthew R Groves
Journal: J Med Chem Date: 2021-07-30 Impact factor: 7.446